Description: Dyne Therapeutics is building a leading muscle disease company focused on advancing innovative life-transforming therapeutics for patients with genetically driven diseases. The Company utilizes its proprietary FORCE™ platform to overcome the current limitations of muscle tissue delivery with modern oligonucleotide therapeutic candidates. Dyne is developing a broad portfolio of therapeutics for muscle diseases, including lead programs in myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD) and facioscapulohumeral muscular dystrophy (FSHD).
Home Page: www.dyne-tx.com
DYN Technical Analysis
1560 Trapelo Road
Waltham,
MA
02451
United States
Phone:
781 786 8230
Officers
| Name | Title |
|---|---|
| Mr. Joshua T. Brumm | CEO, Pres & Director |
| Ms. Susanna Gatti High M.B.A. | Chief Operating Officer |
| Dr. Oxana Beskrovnaya Ph.D. | Chief Scientific Officer |
| Dr. Romesh Subramanian Ph.D. | Co-Founder & Advisor |
| Mr. Gene Kim | VP of Fin. |
| Mr. Richard William Scalzo M.B.A. | Sr. VP, Head of Fin. & Admin. and Treasurer |
| Ms. Amy Reilly | Sr. VP and Head of Corp. Communications & Investor Relations |
| Ms. Kate Mitchell | VP & Head of HR |
| Dr. Thomas-Christian Mix M.D., M.S. | Sr. VP of Pharmacovigilance |
| Ms. Debra Feldman | Sr. VP & Head of Regulatory Affairs |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Utilities |
|---|---|
| GIC Group: | Utilities |
| GIC Industry: | Independent Power and Renewable Electricity Producers |
| GIC Sub-Industry: | Independent Power Producers & Energy Traders |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 2.2375 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2020-09-17 |
| Fiscal Year End: | December |
| Full Time Employees: | 115 |